“Estimated Conjunctivitis-Related Healthcare Cost Savings With Increased Tralokinumab Use Versus Other Biologics Among Patients With Moderate-Severe Atopic Dermatitis in the United States” (2025) SKIN The Journal of Cutaneous Medicine, 9(6), p. s630. doi:10.25251/ej4zcr36.